1-8 of 8
G. Yancey Gillespie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers

Kyung-Don Kang, Joshua D. Bernstock, Stacie K. Totsch, Sam E. Gary, Abbey Rocco, Li Nan, Rong Li, Tina Etminan, Xiaosi Han, Elizabeth A. Beierle, Tanja Eisemann, Robert J. Wechsler-Reya, Sejong Bae, Richard Whitley, G. Yancey Gillespie, James M. Markert, Gregory K. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5419–5430.
https://doi.org/10.1158/1078-0432.CCR-22-1382
Published: 15 December 2022
View article titled, Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Open the PDF for Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers in another window
Includes: Supplementary data
Journal Articles

Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study

Katherine E. Miller, Kevin A. Cassady, Justin C. Roth, Jennifer Clements, Kathleen M. Schieffer, Kristen Leraas, Anthony R. Miller, Nripesh Prasad, Jianmei W. Leavenworth, Inmaculada B. Aban, Richard J. Whitley, G. Yancey Gillespie, Elaine R. Mardis, James M. Markert
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 498–506.
https://doi.org/10.1158/1078-0432.CCR-21-2636
Published: 01 February 2022
View article titled, Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Open the PDF for Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study in another window
Includes: Supplementary data
Journal Articles

Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy

Eric K. Ring, James M. Markert, G. Yancey Gillespie, Gregory K. Friedman
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (2): 342–350.
https://doi.org/10.1158/1078-0432.CCR-16-1829
Published: 15 January 2017
View article titled, Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy
Open the PDF for Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy in another window
Journal Articles

MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma

John S. Jarboe, Joshua C. Anderson, Christine W. Duarte, Tapan Mehta, Somaira Nowsheen, Patricia H. Hicks, Alexander C. Whitley, Timothy D. Rohrbach, Raymond O. McCubrey, Sherard Chiu, Tamara M. Burleson, James A. Bonner, G. Yancey Gillespie, Eddy S. Yang, Christopher D. Willey
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (11): 3030–3041.
https://doi.org/10.1158/1078-0432.CCR-11-3091
Published: 31 May 2012
View article titled, MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Open the PDF for MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma in another window
Includes: Supplementary data
Journal Articles

Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression

Emily C. Brantley, L. Burton Nabors, G. Yancey Gillespie, Youn-Hee Choi, Cheryl Ann Palmer, Keith Harrison, Kevin Roarty, Etty N. Benveniste
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15): 4694–4704.
https://doi.org/10.1158/1078-0432.CCR-08-0618
Published: 01 August 2008
View article titled, Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression
Open the PDF for Loss of Protein Inhibitors of Activated STAT-3 Expression in Glioblastoma Multiforme Tumors: Implications for STAT-3 Activation and Gene Expression in another window
Includes: Supplementary data
Journal Articles

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.

K Jin Kim, Lihong Wang, Yi-Chi Su, G Yancey Gillespie, Amandeep Salhotra, Bachchu Lal, John Laterra
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (4): 1292–1298.
https://doi.org/10.1158/1078-0432.CCR-05-1793
Published: 17 February 2006
View article titled, Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Open the PDF for Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. in another window
Journal Articles

Ionizing Radiation Improves Survival in Mice Bearing Intracranial High-Grade Gliomas Injected with Genetically Modified Herpes Simplex Virus

Jeffrey D. Bradley, Yasushi Kataoka, Sunil Advani, Su Mi Chung, Ramin B. Arani, G. Yancey Gillespie, Richard J. Whitley, James M. Markert, Bernard Roizman, Ralph R. Weichselbaum
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (6): 1517–1522.
Published: 01 June 1999
View article titled, Ionizing Radiation Improves Survival in Mice Bearing Intracranial High-Grade Gliomas Injected with Genetically Modified Herpes Simplex Virus
Open the PDF for Ionizing Radiation Improves Survival in Mice Bearing Intracranial High-Grade Gliomas Injected with Genetically Modified Herpes Simplex Virus in another window
Journal Articles

Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas

Waldemar Debinski, Denise M. Gibo, Stanley W. Hulet, James R. Connor, G. Yancey Gillespie
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (5): 985–990.
Published: 01 May 1999
View article titled, Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas
Open the PDF for Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas in another window